ClinicalTrials.gg
CompletedNCT04159519Updated Jan 9, 2025Results posted

A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab

A Phase 4 interventional study of Symbicort® and Fasenra® in Asthma and Severe Eosinophilic Asthma, sponsored by AstraZeneca. Completed at 23 sites in 4 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2025-01-09.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.

Enrollment
15th of 39
170 · median 128
Started
2020
the only one that year
Phase 4
9 of 39
2 open now
Registered
29th of 39
by date
Lead sponsor
24 of 39
AstraZeneca

Among the 39 studies testing benralizumab in Asthma, this one is the 15th largest by enrollment, is the only one that started in 2020, is one of 9 in phase 4, and was the 29th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About benralizumab

benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing benralizumab in Asthma, or all of them as a file.
02

Study summary

This is a multicentre, randomised, open-label, parallel-group, active-controlled, phase IV study to assess the reduction of daily Symbicort® maintenance to anti-inflammatory reliever treatment only in participants with severe eosinophilic asthma on Fasenra® treatment, while maintaining asthma control.

Read the detailed description

This study will be conducted at 24 study sites in 3-5 countries. The study duration for each participant will be approximately 52-56 weeks. Approximately 240 participants with severe eosinophilic asthma taking high-dose Inhaled corticosteroids/ long-acting β2-agonist (ICS/LABA) who have been treated for severe eosinophilic asthma with at least 3 consecutive doses of Fasenra® and have clinically responded since the start of Fasenra® treatment (defined for the purpose of this study as an Asthma control questionnaire-5 item (ACQ-5 score) \<1.5 at Visit 1 and Visit 2b) will be enrolled into this open-label study. The study consists of a Screening Visit (Visit 1) and 4- to 8-week screening and run-in period (to align the randomisation study visit with the next Fasenra® injection), a reduction period of 32 weeks, and a 16-week maintenance period.

03

Conditions studied

  • Asthma
  • Severe Eosinophilic Asthma

Browse trials for

Keywords

  • Anti-Inflammatory
  • Reduction period
  • Inhaled corticosteroids
  • long-acting β2 agonist
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of prior to any study-specific procedures.
  2. Patient must be aged 18 years old or above at the time of consenting to study participation.
  3. Documented current maintenance treatment with high-dose ICS/LABA.
  4. ACQ-5 score \<1.5 at Visit 1.
  5. Treatment with Fasenra® for the indicated diagnosis of severe eosinophilic asthma and has received at least 3 consecutive doses (>8 weeks) prior to Visit 1.
  6. Male or female.
  7. Negative serum pregnancy test at Visit 1 for women of (WOCBP).
  8. WOCBP must agree to use a highly effective method of (confirmed by the Investigator) from randomisation throughout the study duration and within 12 weeks after the last dose of study treatment. Highly effective forms of birth control (those that can achieve a failure rate of less than 1% per year when used consistently and correctly) include:

    • Combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation-oral, intravaginal, or transdermal.
    • Progestogen-only hormonal contraception associated with inhibition of ovulation-oral, injectable, or implantable.
    • Intrauterine device (IUD).
    • Intrauterine hormone-releasing system (IUS).
    • Bilateral tubal occlusion.
    • Sexual abstinence, ie, refraining from heterosexual intercourse (the reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient).
    • Vasectomised sexual partner (provided that partner is the sole sexual partner of the WOCBP study patient and that the vasectomised partner has received medical assessment of the surgical success).

Women not of childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are . Women will be considered postmenopausal if they have been amenorrhoeic for ≥12 months prior to the planned date of randomisation without an alternative medical cause.

The following age-specific requirements apply:

  • Women \<50 years old will be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatment and have follicle stimulating hormone (FSH) levels in the postmenopausal range. Until FSH is documented to be within menopausal range, treat the patient as WOCBP.
  • Women ≥50 years old will be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatment.

For randomisation at Visit 2b, patients should fulfil the following criteria:

  1. ACQ-5 \<1.5 at Visit 2b.
  2. No increase (worsening) in ACQ-5 of at least ≥0.5 units between Visit 1 and Visit 2b compared to baseline.
  3. No asthma exacerbation (see Section 8.1.3) between Visit 1 and Visit 2b.
  4. No use of Ventolin® for symptom worsening in >3 out of the 7 days prior to Visit 2b.

Exclusion criteria

Exclusion Criteria:

  1. As judged by the Investigator, any evidence of a severe or serious treatment-related AE during Fasenra® treatment which in the Investigator's opinion makes it undesirable for the patient to participate in the study.
  2. History of exacerbation requiring systemic or hospitalisation during the last 3 months prior to Visit 1 or during the run-in period.
  3. pulmonary disease other than asthma (eg, active lung infection, (COPD), bronchiectasis, pulmonary fibrosis, cystic fibrosis), or ever been diagnosed with pulmonary or systemic disease, other than asthma, that are associated with elevated peripheral eosinophil counts (eg, allergic bronchopulmonary aspergillosis/mycosis, Churg-Strauss syndrome, hypereosinophilic syndrome).
  4. Current smokers or former smokers with a smoking history ≥20 pack/years.
  5. History of alcohol or drug abuse within 12 months prior to Visit 1.
  6. A helminth parasitic infection diagnosed within 24 weeks prior to Visit 1 that has not been treated with, or has failed to respond to, standard of care therapy.
  7. History of anaphylaxis to any biologic therapy.
  8. Known history of allergy or reaction to any component of the study treatment formulation.
  9. A history of known immunodeficiency disorder, including history of a positive (HIV) test.
  10. Current , or history of malignancy, except for:

    • Patients who have had basal cell carcinoma, localized squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible provided that the patient is in remission and curative therapy was completed at least 12 months prior to the date was obtained.
    • Patients who have had other malignancies are eligible provided that the patient is in remission and curative therapy was completed at least 5 years prior to the date informed consent was obtained.

    Prior/Concomitant Therapy

  11. Oral corticosteroid use during the last 3 months prior to Visit 1.
  12. Receipt of long-acting muscarinic antagonist (LAMAs) or theophyllines from Visit 1 until after Visit 8b, or leukotriene receptor antagonist (LTRAs) from Visit 2b until after Visit 8b.
  13. Use of medication (including but not limited to: methotrexate, troleandomycin, cyclosporine, azathioprine, intramuscular long-acting depot corticosteroid, or any experimental anti-inflammatory therapy) within 3 months or 5 half-lives (whichever is longer) prior to the date informed consent is obtained.
  14. Receipt of 30 days prior to Visit 1.
  15. It is recommended to allow receipt of inactive/killed vaccinations (eg, inactive influenza) provided they are not administered within 1 week before/after any study treatment administration.
  16. It is recommended to allow receipt of coronavirus disease 2019 (COVID-19) vaccination prior to study start provided such patients are not randomized until >30 days after last vaccine dose.
  17. It is recommended to allow allergen immunotherapy provided it is stable for at least 30 days prior to Visit 1 and there is no anticipated change during the treatment period. Allergen immunotherapy should not be administered on the same day as study visits.
  18. Receipt of immunoglobulin or blood products within 30 days prior to the date informed consent is obtained.
  19. Five-lipoxygenase inhibitors (eg, zileuton) are prohibited and are not allowed within 30 days of Visit 1 and until after Visit 8b.
  20. Receipt of any marketed (eg, omalizumab) or biologic within 4 months or 5 half-lives prior to the date informed consent is obtained, whichever is longer.
  21. Receipt of systemic treatment with strong inhibitors (eg, ketoconazole and itraconazole) from Visit 1 until after Visit 8b.
  22. Receipt of beta-adrenergic blockers (including eye drops) from Visit 1 until after Visit 8b.
  23. Concurrent participation in another clinical study with an Investigational Product or a post-authorisation safety study.

    Other Exclusions

  24. Planned surgical procedures or other planned life events during the conduct of the study that would affect the patient's ability to comply with study treatment dosing or study assessments.
  25. Involvement in the planning and/or conduct of the study (applies to both AZ staff and/or staff at the study site).
  26. Judgement by the Investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
  27. Prior randomisation in the present study.
  28. Currently pregnant, breast-feeding, or lactating women.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
170 participants (actual)

Study arms

  • Experimental
    Treatment reduction arm

    Participants will receive Benralizumab 30 mg every 8 weeks (Q8W) during the study period, and high-dose Symbicort maintenance 400/12 μg ×2 inhalations BID + Ventolin (salbutamol 100 μg) reliever as needed (PRN), tapering to, medium-dose Symbicort 200/6 μg ×2 inhalations BID maintenance + Symbicort 200/6 μg reliever PRN, low dose Symbicort 200/6 μg x 1 inhalation BID maintenance + Symbicort 200/6 μg reliever PRN; or Symbicort 200/6 μg reliever only, as per tapering scheme and depending on the degree of asthma control). The reduction period in this arm lasted for 32 weeks.

    Drug: Symbicort® · Drug: Fasenra® · Drug: Ventolin®

  • Experimental
    Reference arm

    Participants will receive Benralizumab 30 mg Q8W + high-dose Symbicort® 400/12 μg maintenance ×2 inhalations BID + Ventolin® (salbutamol 100 μg) reliever PRN therapy. Eligible participants randomised to the reference arm continued on high-dose Symbicort® maintenance treatment and Ventolin® reliever treatment.

    Drug: Symbicort® · Drug: Fasenra® · Drug: Ventolin®

Interventions

  • DrugSymbicort®

    Participants will receive Budesonide 400 μg/formoterol fumarate 12 μg per inhalation or Budesonide 200 μg/formoterol fumarate 6 μg per inhalation.

    Also known as: budesonide/formoterol

  • Participants will receive Benralizumab 30 mg/mL, 1 mL fill volume via subcutaneous injection every 4 weeks for first 3 doses (prior to study inclusion), every 8 weeks thereafter.

    Also known as: benralizumab

  • Participants will receive Salbutamol sulfate 100 μg per inhalation as needed.

    Also known as: salbutamol

06

What researchers measure

Primary outcomes

  1. Proportion of Patients Who Reduced Their Symbicort® Maintenance Dose at the End of the Reduction Period

    Proportion of patients with non-missing Week 32 dose who reduced their Symbicort® maintenance dose at the end of the reduction period (Week 32) to: a) Medium-dose Symbicort® maintenance and reliever therapy (SMART), or b) Low-dose SMART, or c) Symbicort® anti-inflammatory reliever only.

    Time frame: At Week 32

Secondary outcomes

  1. Change From Baseline in Asthma Control Questionnaire-5 Item (ACQ-5) Score at the End of the Reduction Period

    Change from baseline in the ACQ-5 patient reported outcome. This instrument contains 5 asthma symptom questions, rated from 0 (total control) to 6 (severely uncontrolled). The ACQ-5 score is the mean of the responses. Mean scores ≤0.75 indicate well controlled, scores between \>0.75 and \<1.5 indicate partly controlled, ≥1.5 indicate not well controlled asthma, and individual changes of ≥0.5 are considered to be clinically meaningful. ACQ-5 deterioration is defined as at least a 0.5 unit increase in ACQ-5 score from baseline, and a decrease of at least 0.5 units from baseline indicates improved asthma control.

    Time frame: Week 0 (baseline) and at Week 32

  2. Change From Baseline in Standardised Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(S)+12) at the End of the Reduction Period

    The AQLQ(S)+12 is a Patient-Reported Outcome (PRO) that measures the health-related quality of life experienced by asthma patients. The questionnaire comprises 4 separate domains (symptoms, activity limitations, emotional function, and environmental stimuli). Patients are asked to recall their experiences during the previous 2 weeks before each visit and to score each of the questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). Range of Total Score = 0 - 7 as it is an average of responses to the individual questions. High score = better quality of life, and low score = poor quality of life. Change of \>0.5 from baseline is considered a meaningful improvement in score.

    Time frame: Week 0 (baseline) and at Week 32

  3. Number of Patients With no Deterioration in AQLQ(S)+12 at the End of the Reduction Period

    The AQLQ(S)+12 is a PRO that measures the health-related quality of life experienced by asthma patients. The questionnaire comprises 4 separate domains (symptoms, activity limitations, emotional function, and environmental stimuli). Patients are asked to recall their experiences during the previous 2 weeks before each visit and to score each of the questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). AQLQ(S)+12 deterioration was defined as at least a 0.5 unit decrease in AQLQ(S)+12 total score from baseline. Patients with no deterioration include patients with improvement or no change.

    Time frame: At Week 32

  4. Number of Patients With no Deterioration in ACQ-5 at the End of the Reduction Period

    Change from baseline in the ACQ-5 patient reported outcome. This instrument contains 5 asthma symptom questions, rated from 0 (total control) to 6 (severely uncontrolled). The ACQ-5 score is the mean of the responses. Mean scores ≤0.75 indicate well controlled, scores between \>0.75 and \<1.5 indicate partly controlled, ≥1.5 indicate not well controlled asthma, and individual changes of ≥0.5 are considered to be clinically meaningful. ACQ-5 deterioration is defined as at least a 0.5 units increase in ACQ-5 score from baseline, and a decrease of at least 0.5 units from baseline indicates improved asthma control.

    Time frame: At Week 32

  5. Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) During the Study Period

    The potential for benralizumab-treated patients to maintain lung function while stepping down Symbicort® maintenance treatment was assessed. The FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration, expressed in liters. Change from baseline pre-bronchodilator FEV1 calculated as post-baseline pre-bronchodilator FEV1 (L) minus baseline pre-bronchodilator FEV1 (L) for all post-baseline measurement points.

    Time frame: At Week 0 (baseline), and at Weeks 8, 16, 24, 32, 40, and 48

  6. Annualised Asthma Exacerbation Rate During the Study Period

    Asthma exacerbation rate was assessed. An asthma exacerbation was defined as a worsening of asthma symptoms that led to any of the following: a) Temporary bolus/burst of systemic corticosteroids (≥3 consecutive days); b) Single depo-injectable dose of corticosteroids (equivalent to a 3-day bolus/burst); c) Visit to emergency room/urgent care (treatment \<24 hours) requiring systemic corticosteroids; d) Hospitalization (admission/evaluation ≥24 hours) due to asthma.

    Time frame: From Week 0 up to Week 48

  7. Cumulative Total Daily Inhaled Corticosteroids (ICS) Dose, by Period

    The cumulative total daily ICS dose (maintenance +reliever) for: a) reduction period; b) maintenance period; c) study period was assessed.

    Time frame: Reduction period (From Week 0 up to Week 32); maintenance period (From Week 32 up to Week 48); Study period (Week 0 up to end of maintenance period/ end of study)

  8. Total Daily ICS Dose (Maintenance + Reliever) at the End of the Reduction Period

    The mean total daily ICS dose (maintenance + reliever) during the 8 weeks prior to end of the reduction period was assessed.

    Time frame: At Week 32

  9. Proportion of Participants Using the Same Symbicort® Daily Dose at the End of the Maintenance Period (Week 48) That They Achieved at the End of the Reduction Period (Week 32)

    Proportion of patients using the same Symbicort daily dose at the end of the maintenance period that they achieved at the end of the reduction period. Proportions were based on patients with non-missing Week 32 and Week 48 Symbicort doses.

    Time frame: At Week 48

  10. Number of Patients With at Least 1 Exacerbation Occurring From End of the Reduction Period to End of the Maintenance Period

    Number of patients with at least 1 exacerbation occurring from end of the reduction period to end of the maintenance period.

    Time frame: From Week 32 to Week 48

  11. Total Daily ICS Dose From the End of the Reduction Period to the End of the Maintenance Period

    Total daily ICS dose from the end of the reduction period to the end of the maintenance period.

    Time frame: Week 32, Week 40, and Week 48

  12. Change in ACQ-5 From the End of the Reduction Period to the End of the Maintenance Period

    Change in ACQ-5 score from end of reduction to end of maintenance is reported. This instrument contains 5 asthma symptom questions, rated from 0 (total control) to 6 (severely uncontrolled). The ACQ-5 score is the mean of the responses. Mean scores ≤0.75 indicate well controlled, scores between \>0.75 and \<1.5 indicate partly controlled, ≥1.5 indicate not well controlled asthma, and individual changes of ≥0.5 are considered to be clinically meaningful. ACQ-5 deterioration is defined as at least a 0.5 unit increase in ACQ-5 score from baseline, and a decrease of at least 0.5 units from baseline indicates improved asthma control.

    Time frame: From Week 32 to Week 48

  13. Change in AQLQ(S)+12 From the End of the Reduction Period to the End of the Maintenance Period

    Change in AQLQ(S)+12 from the end of the reduction period to the end of the maintenance period is reported. The AQLQ(S)+12 is a Patient-Reported Outcome (PRO) that measures the health-related quality of life experienced by asthma patients. The questionnaire comprises 4 separate domains (symptoms, activity limitations, emotional function, and environmental stimuli). Patients are asked to recall their experiences during the previous 2 weeks before each visit and to score each of the questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). Range of Total Score = 0 - 7 as it is an average of responses to the individual questions. High score = better quality of life, and low score = poor quality of life. Change of \>0.5 from baseline is considered a meaningful improvement in score.

    Time frame: From Week 32 to Week 48

  14. Change in FEV1 From the End of the Reduction Period to the End of the Maintenance Period

    The change from the end of the reduction period to the end of the maintenance period for pre-bronchodilator Forced Expiratory Volume in 1 second (FEV1) was calculated as Week 48 pre-bronchodilator FEV1 (Liter \[L\]) minus the maintenance period baseline pre-bronchodilator FEV1 (L). The FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration, expressed in liters.

    Time frame: From Week 32 to Week 48

  15. Number of Patients That Met Each Composite Endpoint Defining Clinical Remission

    The number of patients meeting each individual component of the composite endpoint defining clinical remission (zero exacerbations, ACQ-5 \< 1.5, or ACQ-5 \<= 0.75, \< 10% FEV1 deterioration) at the end of reduction and maintenance periods were assessed.

    Time frame: At Week 32 and Week 48

  16. Number of Patients That Met 0, 1, 2, and All 3 Composite Remission Endpoints

    Clinical remission in patients at end of the reduction and maintenance periods was assessed. A remission score, assigning 1 point for each clinical remission component achieved at week 32 or week 48,was calculated for patients who met 0, 1, 2, and all 3 remission criteria (zero exacerbations,ACQ-5 \< 1.5, or ACQ-5 \<= 0.75,\< 10% FEV1 deterioration). Total remission score ranges from 0 to 3. The higher the score, the more components of remission the patient achieved.

    Time frame: At Week 32 and Week 48

  17. Number of Patients With Adverse Events or Serious Adverse Events

    The safety and tolerability of benralizumab in patients with severe asthma, while stepping down Symbicort® maintenance treatment and maintaining asthma symptom control was assessed.

    Time frame: From Week 0 (randomization) to Week 48 or end of treatment (total period of study is 2.5 years)

07

Results

Posted Jan 9, 2025
Limitations and caveats
In the CSR synopsis dated 11 September 2023, One patient was erroneously excluded from analysis. Correct count reveals 11 patients in the treatment reduction arm experienced at least one asthma exacerbation during treatment reduction period, resulting in a total of 11 exacerbations. As a consequence, analysis outputs for asthma exacerbation and remission have been affected, for which CSR errata have been submitted along with redaction package.

Participant flow

The study was conducted between 27 July 2020 and 31 January 2023.

Participant flow — Overall Study
MilestoneTreatment ReductionReference
Started12543
Completed11737
Not completed86
Withdrew: Adverse event11
Withdrew: Lack of efficacy10
Withdrew: Discontinued from study10
Withdrew: Protocol violation11
Withdrew: Withdrawal by subject44

Outcome measures

PrimaryProportion of Patients Who Reduced Their Symbicort® Maintenance Dose at the End of the Reduction Period

Proportion of patients with non-missing Week 32 dose who reduced their Symbicort® maintenance dose at the end of the reduction period (Week 32) to: a) Medium-dose Symbicort® maintenance and reliever therapy (SMART), or b) Low-dose SMART, or c) Symbicort® anti-inflammatory reliever only.

Time frame:
At Week 32
Reported as:
Number · Proportion of Participants
Proportion of Patients Who Reduced Their Symbicort® Maintenance Dose at the End of the Reduction Period
Proportion of ParticipantsTreatment Reduction
Medium-dose SMART0.151 (0.0922 to 0.2285)
Low-dose SMART0.168 (0.1058 to 0.2476)
Symbicort® reliever-only dose0.605 (0.5113 to 0.6934)
SecondaryChange From Baseline in Asthma Control Questionnaire-5 Item (ACQ-5) Score at the End of the Reduction Period

Change from baseline in the ACQ-5 patient reported outcome. This instrument contains 5 asthma symptom questions, rated from 0 (total control) to 6 (severely uncontrolled). The ACQ-5 score is the mean of the responses. Mean scores ≤0.75 indicate well controlled, scores between \>0.75 and \<1.5 indicate partly controlled, ≥1.5 indicate not well controlled asthma, and individual changes of ≥0.5 are considered to be clinically meaningful. ACQ-5 deterioration is defined as at least a 0.5 unit increase in ACQ-5 score from baseline, and a decrease of at least 0.5 units from baseline indicates improved asthma control.

Time frame:
Week 0 (baseline) and at Week 32
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Asthma Control Questionnaire-5 Item (ACQ-5) Score at the End of the Reduction Period
Score on a scaleTreatment ReductionReference
Change From Baseline in Asthma Control Questionnaire-5 Item (ACQ-5) Score at the End of the Reduction Period0.1617 ± 0.03930.0555 ± 0.0677
Statistical analysis
  • Treatment Reduction vs Reference · Least square mean difference: 0.1062 · 95% CI -0.0485 to 0.2609
SecondaryChange From Baseline in Standardised Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(S)+12) at the End of the Reduction Period

The AQLQ(S)+12 is a Patient-Reported Outcome (PRO) that measures the health-related quality of life experienced by asthma patients. The questionnaire comprises 4 separate domains (symptoms, activity limitations, emotional function, and environmental stimuli). Patients are asked to recall their experiences during the previous 2 weeks before each visit and to score each of the questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). Range of Total Score = 0 - 7 as it is an average of responses to the individual questions. High score = better quality of life, and low score = poor quality of life. Change of \>0.5 from baseline is considered a meaningful improvement in score.

Time frame:
Week 0 (baseline) and at Week 32
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Standardised Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(S)+12) at the End of the Reduction Period
Score on a scaleTreatment ReductionReference
Change From Baseline in Standardised Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(S)+12) at the End of the Reduction Period-0.0279 ± 0.05590.0064 ± 0.0950
Statistical analysis
  • Treatment Reduction vs Reference · Mixed model for repeated measure (MMRM) · Least square mean difference: -0.0343 · 95% CI -0.2527 to 0.1841MMRM with fixed effects for treatment arm, visit, baseline value, and treatment-by-visit interaction with an unstructured covariance structure.
SecondaryNumber of Patients With no Deterioration in AQLQ(S)+12 at the End of the Reduction Period

The AQLQ(S)+12 is a PRO that measures the health-related quality of life experienced by asthma patients. The questionnaire comprises 4 separate domains (symptoms, activity limitations, emotional function, and environmental stimuli). Patients are asked to recall their experiences during the previous 2 weeks before each visit and to score each of the questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). AQLQ(S)+12 deterioration was defined as at least a 0.5 unit decrease in AQLQ(S)+12 total score from baseline. Patients with no deterioration include patients with improvement or no change.

Time frame:
At Week 32
Reported as:
Count of participants · Participants
Number of Patients With no Deterioration in AQLQ(S)+12 at the End of the Reduction Period
ParticipantsTreatment ReductionReference
Improvement123
No change7328
SecondaryNumber of Patients With no Deterioration in ACQ-5 at the End of the Reduction Period

Change from baseline in the ACQ-5 patient reported outcome. This instrument contains 5 asthma symptom questions, rated from 0 (total control) to 6 (severely uncontrolled). The ACQ-5 score is the mean of the responses. Mean scores ≤0.75 indicate well controlled, scores between \>0.75 and \<1.5 indicate partly controlled, ≥1.5 indicate not well controlled asthma, and individual changes of ≥0.5 are considered to be clinically meaningful. ACQ-5 deterioration is defined as at least a 0.5 units increase in ACQ-5 score from baseline, and a decrease of at least 0.5 units from baseline indicates improved asthma control.

Time frame:
At Week 32
Reported as:
Count of participants · Participants
Number of Patients With no Deterioration in ACQ-5 at the End of the Reduction Period
ParticipantsTreatment ReductionReference
Improvement62
No change8728
SecondaryChange From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) During the Study Period

The potential for benralizumab-treated patients to maintain lung function while stepping down Symbicort® maintenance treatment was assessed. The FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration, expressed in liters. Change from baseline pre-bronchodilator FEV1 calculated as post-baseline pre-bronchodilator FEV1 (L) minus baseline pre-bronchodilator FEV1 (L) for all post-baseline measurement points.

Time frame:
At Week 0 (baseline), and at Weeks 8, 16, 24, 32, 40, and 48
Reported as:
Least squares mean · Liter
Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) During the Study Period
LiterTreatment ReductionReference
Week 80.0411 ± 0.01830.0549 ± 0.0315
Week 160.0299 ± 0.02150.0115 ± 0.0363
Week 24-0.0536 ± 0.03170.0644 ± 0.0540
Week 32-0.0824 ± 0.0285-0.0016 ± 0.0482
Week 40-0.0953 ± 0.02800.0428 ± 0.0476
Week 48-0.0889 ± 0.02720.0059 ± 0.0475
SecondaryAnnualised Asthma Exacerbation Rate During the Study Period

Asthma exacerbation rate was assessed. An asthma exacerbation was defined as a worsening of asthma symptoms that led to any of the following: a) Temporary bolus/burst of systemic corticosteroids (≥3 consecutive days); b) Single depo-injectable dose of corticosteroids (equivalent to a 3-day bolus/burst); c) Visit to emergency room/urgent care (treatment \<24 hours) requiring systemic corticosteroids; d) Hospitalization (admission/evaluation ≥24 hours) due to asthma.

Time frame:
From Week 0 up to Week 48
Reported as:
Number · Events/Year
Annualised Asthma Exacerbation Rate During the Study Period
Events/YearTreatment ReductionReference
Annualised Asthma Exacerbation Rate During the Study Period0.14 (0.09 to 0.23)0.14 (0.06 to 0.31)
SecondaryCumulative Total Daily Inhaled Corticosteroids (ICS) Dose, by Period

The cumulative total daily ICS dose (maintenance +reliever) for: a) reduction period; b) maintenance period; c) study period was assessed.

Time frame:
Reduction period (From Week 0 up to Week 32); maintenance period (From Week 32 up to Week 48); Study period (Week 0 up to end of maintenance period/ end of study)
Reported as:
Mean · Microgram
Cumulative Total Daily Inhaled Corticosteroids (ICS) Dose, by Period
MicrogramTreatment ReductionReference
Reduction period115956.8 ± 73223.93312857.1 ± 81251.22
Maintenance period50984.3 ± 51148.59150400.0 ± 42180.46
Study period157560.0 ± 114123.69448933.3 ± 131247.22
SecondaryTotal Daily ICS Dose (Maintenance + Reliever) at the End of the Reduction Period

The mean total daily ICS dose (maintenance + reliever) during the 8 weeks prior to end of the reduction period was assessed.

Time frame:
At Week 32
Reported as:
Mean · Microgram
Total Daily ICS Dose (Maintenance + Reliever) at the End of the Reduction Period
MicrogramTreatment ReductionReference
Total Daily ICS Dose (Maintenance + Reliever) at the End of the Reduction Period380.028 ± 440.49951401.796 ± 316.9718
SecondaryProportion of Participants Using the Same Symbicort® Daily Dose at the End of the Maintenance Period (Week 48) That They Achieved at the End of the Reduction Period (Week 32)

Proportion of patients using the same Symbicort daily dose at the end of the maintenance period that they achieved at the end of the reduction period. Proportions were based on patients with non-missing Week 32 and Week 48 Symbicort doses.

Time frame:
At Week 48
Reported as:
Number · Proportion
Proportion of Participants Using the Same Symbicort® Daily Dose at the End of the Maintenance Period (Week 48) That They Achieved at the End of the Reduction Period (Week 32)
ProportionTreatment Reduction
Proportion of Participants Using the Same Symbicort® Daily Dose at the End of the Maintenance Period (Week 48) That They Achieved at the End of the Reduction Period (Week 32)0.958 (0.9039 to 0.9861)
SecondaryNumber of Patients With at Least 1 Exacerbation Occurring From End of the Reduction Period to End of the Maintenance Period

Number of patients with at least 1 exacerbation occurring from end of the reduction period to end of the maintenance period.

Time frame:
From Week 32 to Week 48
Reported as:
Count of participants · Participants
Number of Patients With at Least 1 Exacerbation Occurring From End of the Reduction Period to End of the Maintenance Period
ParticipantsTreatment ReductionReference
Number of Patients With at Least 1 Exacerbation Occurring From End of the Reduction Period to End of the Maintenance Period54
SecondaryTotal Daily ICS Dose From the End of the Reduction Period to the End of the Maintenance Period

Total daily ICS dose from the end of the reduction period to the end of the maintenance period.

Time frame:
Week 32, Week 40, and Week 48
Reported as:
Mean · Microgram
Total Daily ICS Dose From the End of the Reduction Period to the End of the Maintenance Period
MicrogramTreatment ReductionReference
Week 32383.221 ± 440.96491438.685 ± 220.6355
Week 40408.458 ± 475.69861424.624 ± 321.5752
Week 48376.356 ± 449.66141265.356 ± 472.5244
SecondaryChange in ACQ-5 From the End of the Reduction Period to the End of the Maintenance Period

Change in ACQ-5 score from end of reduction to end of maintenance is reported. This instrument contains 5 asthma symptom questions, rated from 0 (total control) to 6 (severely uncontrolled). The ACQ-5 score is the mean of the responses. Mean scores ≤0.75 indicate well controlled, scores between \>0.75 and \<1.5 indicate partly controlled, ≥1.5 indicate not well controlled asthma, and individual changes of ≥0.5 are considered to be clinically meaningful. ACQ-5 deterioration is defined as at least a 0.5 unit increase in ACQ-5 score from baseline, and a decrease of at least 0.5 units from baseline indicates improved asthma control.

Time frame:
From Week 32 to Week 48
Reported as:
Mean · Score on a scale
Change in ACQ-5 From the End of the Reduction Period to the End of the Maintenance Period
Score on a scaleTreatment ReductionReference
Change in ACQ-5 From the End of the Reduction Period to the End of the Maintenance Period-0.07 ± 0.575-0.20 ± 0.814
SecondaryChange in AQLQ(S)+12 From the End of the Reduction Period to the End of the Maintenance Period

Change in AQLQ(S)+12 from the end of the reduction period to the end of the maintenance period is reported. The AQLQ(S)+12 is a Patient-Reported Outcome (PRO) that measures the health-related quality of life experienced by asthma patients. The questionnaire comprises 4 separate domains (symptoms, activity limitations, emotional function, and environmental stimuli). Patients are asked to recall their experiences during the previous 2 weeks before each visit and to score each of the questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). Range of Total Score = 0 - 7 as it is an average of responses to the individual questions. High score = better quality of life, and low score = poor quality of life. Change of \>0.5 from baseline is considered a meaningful improvement in score.

Time frame:
From Week 32 to Week 48
Reported as:
Mean · Score on a scale
Change in AQLQ(S)+12 From the End of the Reduction Period to the End of the Maintenance Period
Score on a scaleTreatment ReductionReference
Change in AQLQ(S)+12 From the End of the Reduction Period to the End of the Maintenance Period-0.008 ± 0.47200.060 ± 0.5658
SecondaryChange in FEV1 From the End of the Reduction Period to the End of the Maintenance Period

The change from the end of the reduction period to the end of the maintenance period for pre-bronchodilator Forced Expiratory Volume in 1 second (FEV1) was calculated as Week 48 pre-bronchodilator FEV1 (Liter \[L\]) minus the maintenance period baseline pre-bronchodilator FEV1 (L). The FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration, expressed in liters.

Time frame:
From Week 32 to Week 48
Reported as:
Mean · Liter
Change in FEV1 From the End of the Reduction Period to the End of the Maintenance Period
LiterTreatment ReductionReference
Change in FEV1 From the End of the Reduction Period to the End of the Maintenance Period0.0089 ± 0.23200.0040 ± 0.2264
SecondaryNumber of Patients That Met Each Composite Endpoint Defining Clinical Remission

The number of patients meeting each individual component of the composite endpoint defining clinical remission (zero exacerbations, ACQ-5 \< 1.5, or ACQ-5 \<= 0.75, \< 10% FEV1 deterioration) at the end of reduction and maintenance periods were assessed.

Time frame:
At Week 32 and Week 48
Reported as:
Count of participants · Participants
Number of Patients That Met Each Composite Endpoint Defining Clinical Remission
ParticipantsTreatment ReductionReference
No asthma exacerbation at Week 3210837
No asthma exacerbation at Week 4810132
ACQ-5 <1.5 at Week 3210632
ACQ-5 <1.5 at Week 4810332
ACQ-5 ≤ 0.75 at Week 326521
ACQ-5 ≤ 0.75 at Week 486821
FEV1 < 10% decrease from baseline at Week 325926
FEV1 < 10% decrease from baseline at Week 486623
SecondaryNumber of Patients That Met 0, 1, 2, and All 3 Composite Remission Endpoints

Clinical remission in patients at end of the reduction and maintenance periods was assessed. A remission score, assigning 1 point for each clinical remission component achieved at week 32 or week 48,was calculated for patients who met 0, 1, 2, and all 3 remission criteria (zero exacerbations,ACQ-5 \< 1.5, or ACQ-5 \<= 0.75,\< 10% FEV1 deterioration). Total remission score ranges from 0 to 3. The higher the score, the more components of remission the patient achieved.

Time frame:
At Week 32 and Week 48
Reported as:
Count of participants · Participants
Number of Patients That Met 0, 1, 2, and All 3 Composite Remission Endpoints
ParticipantsTreatment ReductionReference
Remission score (Exacerbation, ACQ-5 ≤ 0.75, FEV1 < 10% decrease from baseline) at Week 32 — 020
Remission score (Exacerbation, ACQ-5 ≤ 0.75, FEV1 < 10% decrease from baseline) at Week 32 — 1155
Remission score (Exacerbation, ACQ-5 ≤ 0.75, FEV1 < 10% decrease from baseline) at Week 32 — 2408
Remission score (Exacerbation, ACQ-5 ≤ 0.75, FEV1 < 10% decrease from baseline) at Week 32 — 32915
Remission score (Exacerbation, ACQ-5 ≤ 0.75, FEV1 < 10% decrease from baseline) at Week 48 — 011
Remission score (Exacerbation, ACQ-5 ≤ 0.75, FEV1 < 10% decrease from baseline) at Week 48 — 1154
Remission score (Exacerbation, ACQ-5 ≤ 0.75, FEV1 < 10% decrease from baseline) at Week 48 — 2419
Remission score (Exacerbation, ACQ-5 ≤ 0.75, FEV1 < 10% decrease from baseline) at Week 48 — 33214
Remission score: Exacerbation, ACQ-5 < 1.5, FEV1 < 10% decrease from baseline at Week 32 — 010
Remission score: Exacerbation, ACQ-5 < 1.5, FEV1 < 10% decrease from baseline at Week 32 — 152
Remission score: Exacerbation, ACQ-5 < 1.5, FEV1 < 10% decrease from baseline at Week 32 — 2325
Remission score: Exacerbation, ACQ-5 < 1.5, FEV1 < 10% decrease from baseline at Week 32 — 34821
Remission score: Exacerbation, ACQ-5 < 1.5, FEV1 < 10% decrease from baseline at Week 48 — 000
Remission score: Exacerbation, ACQ-5 < 1.5, FEV1 < 10% decrease from baseline at Week 48 — 152
Remission score: Exacerbation, ACQ-5 < 1.5, FEV1 < 10% decrease from baseline at Week 48 — 2367
Remission score: Exacerbation, ACQ-5 < 1.5, FEV1 < 10% decrease from baseline at Week 48 — 34819
SecondaryNumber of Patients With Adverse Events or Serious Adverse Events

The safety and tolerability of benralizumab in patients with severe asthma, while stepping down Symbicort® maintenance treatment and maintaining asthma symptom control was assessed.

Time frame:
From Week 0 (randomization) to Week 48 or end of treatment (total period of study is 2.5 years)
Reported as:
Count of participants · Participants
Number of Patients With Adverse Events or Serious Adverse Events
ParticipantsTreatment ReductionReference
Any adverse event (AE)9135
Any AE with outcome = death00
Any serious adverse event (including events with outcome = death)125
Any AE leading to discontinuation of benralizumab31
Any AE leading to discontinuation of Symbicort31
Any AE leading to discontinuation of Ventolin21
Any AE leading to withdrawal from study31

Adverse events

Collected over Run-In period: Week -8 to -4 to Week 0 before randomization (total period of 8 weeks); Treatment Period (Treatment reduction and reference): From Week 0 (Randomization) to Week 48 or end of treatment (total period of study is 2.5 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Run-In Period0/167 (0%)1/167 (0.6%)5/167 (3%)
Treatment Reduction0/125 (0%)12/125 (9.6%)46/125 (36.8%)
Reference0/42 (0%)5/42 (11.9%)20/42 (47.6%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventRun-In PeriodTreatment ReductionReference
Helicobacter infectionInfections and infestations0/1670/1251/42
Atrial flutterCardiac disorders0/1670/1251/42
AsthmaRespiratory, thoracic and mediastinal disorders0/1670/1251/42
Inguinal herniaGastrointestinal disorders0/1670/1251/42
Vaccination complicationInjury, poisoning and procedural complications0/1670/1251/42
InfluenzaInfections and infestations0/1671/1250/42
Lower respiratory tract infectionInfections and infestations0/1671/1250/42
OrchitisInfections and infestations0/1671/1250/42
Periorbital abscessInfections and infestations0/1671/1250/42
Gallbladder adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1671/1250/42
Most frequent other events
Most frequent other events
EventRun-In PeriodTreatment ReductionReference
COVID-19Infections and infestations2/16719/1259/42
NasopharyngitisInfections and infestations3/16710/1257/42
AsthmaRespiratory, thoracic and mediastinal disorders0/16717/1254/42
RhinitisInfections and infestations0/1671/1253/42
BronchitisInfections and infestations0/1677/1251/42

Baseline characteristics

The Full Analysis Set (FAS) included all randomised patients, irrespective of their protocol adherence and continued participation in the study.

Age, Continuous
Age, Continuous(Years)Treatment ReductionReferenceTotal
Mean58.1 ± 12.4456.5 ± 11.7057.7 ± 12.24
Sex: Female, Male
Sex: Female, Male(Participants)Treatment ReductionReferenceTotal
Female692089
Male562379
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment ReductionReferenceTotal
Hispanic or Latino8614
Not Hispanic or Latino9128119
Unknown or Not Reported26935
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Treatment ReductionReferenceTotal
White9531126
Asian022
Other213
Not Reported505
Missing23932
08

Study locations

23 sites
  • Research Site
    Brest Cedex, 29609, France
  • Research Site
    Dijon Cedex, 21079, France
  • Research Site
    Le Kremlin-Bicêtre, 94270, France
  • Research Site
    Lille, 59000, France
  • Research Site
    Lyon Cedex 04, 69317, France
  • Research Site
    Pessac, 33600, France
  • Research Site
    Berlin, 10969, Germany
  • Research Site
    Bonn, 53105, Germany
  • Research Site
    Cottbus, 03050, Germany
  • Research Site
    Hamburg, 20354, Germany
  • Research Site
    Hamburg, 22767, Germany
  • Research Site
    Hannover, 30625, Germany
  • Research Site
    Jena, 7740, Germany
  • Research Site
    Mainz, 55131, Germany
  • Research Site
    Marburg, 35043, Germany
  • Research Site
    München, 81377, Germany
  • Research Site
    Bergamo, 24127, Italy
  • Research Site
    Napoli, 80131, Italy
  • Research Site
    Roma, 00168, Italy
  • Research Site
    Belfast, BT9 7BL, United Kingdom
  • Research Site
    Cambridge, CB2 2QQ, United Kingdom
  • Research Site
    London, SE1 9RT, United Kingdom
  • Research Site
    Nottingham, NG15 1PB, United Kingdom
09

References and documents

Publications

  • Butler CA, Heaney LG. Fractional exhaled nitric oxide and asthma treatment adherence. Curr Opin Allergy Clin Immunol. 2021 Feb 1;21(1):59-64. doi: 10.1097/ACI.0000000000000704. PubMed 33369570 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Jan 2023, 30 months.

Results were first posted in Jan 2025, 1 year 11 months after primary completion.

Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 30 months is above that.

Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2019
First posted
Nov 12, 2019
StartActual
Jul 27, 2020
Primary completionActual
Jan 31, 2023
CompletionActual
Jan 31, 2023
Results first posted
Jan 9, 2025
Last update
Jan 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04159519
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 12, 2019
Start date
Jul 27, 2020
Primary completion
Jan 31, 2023
Completion
Jan 31, 2023
Results posted
Jan 9, 2025
Last update
Jan 9, 2025

Study contacts

Dr. David Jackson
principal investigator · Guy's & St Thomas' NHS Trust

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion